Physician profile
James Wesley Sublett
NPI 1255474136
$588,016.54
in general payments reported to CMS, 2019-2025
44 companies · $138K in 2025
The $138K reported for 2025 was more than what 98% of Allergy & Immunology providers received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $71K · 2020: $33K · 2021: $25K · 2022: $64K · 2023: $83K · 2024: $174K · 2025: $138K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $206K · Consulting Fee: $140K · Travel and Lodging: $28K · Food and Beverage: $12K · Honoraria: $7,200 · Grant: $2,700.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $205,925.00 |
| Consulting Fee | $139,941.11 |
| Travel and Lodging | $27,874.57 |
| Food and Beverage | $12,315.48 |
| Honoraria | $7,200.00 |
| Grant | $2,700.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $163,326.06 | 2019-2025 | Airsupra, Tezspire, Fasenra |
| Genzyme Corporation | $135,069.36 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $82,050.05 | 2019-2025 | Dupixent |
| Genentech USA, INC. | $37,557.26 | 2019-2025 | Xolair |
| Incyte Corporation | $28,014.18 | 2022-2025 | Opzelura, Opzelura |
| Kaleo, INC. | $23,667.80 | 2019-2025 | Auvi-Q |
| Dermavant Sciences, INC. | $19,485.76 | 2024 | Tapinarof |
| Amgen INC. | $17,739.48 | 2022-2025 | Tezspire |
| Ionis Pharmaceuticals, INC. | $16,671.63 | 2025 | Dawnzera |
| Optinose US, INC. | $15,637.61 | 2019-2024 | |
| Aimmune Therapeutics, INC. | $11,887.50 | 2020 | |
| Organon LLC | $8,366.74 | 2025 | Vtama |
| Jubilant Hollisterstier LLC | $5,899.34 | 2025 | |
| Merz Pharmaceuticals, LLC | $5,659.71 | 2022 | |
| Pfizer INC. | $5,111.32 | 2019-2024 |
Show all 38 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Hikma Pharmaceuticals USA | $4,344.77 | 2023 | Ryaltris |
| Alk-Abello, INC | $2,500.60 | 2019-2022 | |
| Aquestive Therapeutics, INC. | $2,292.86 | 2025 | |
| Novartis Pharmaceuticals Corporation | $699.66 | 2019-2025 | |
| Glaxosmithkline, LLC. | $494.56 | 2019-2025 | Nucala, Trelegy Ellipta |
| Csl Behring | $400.36 | 2019-2025 | Andembry, Haegarda, Hizentra |
| Teva Pharmaceuticals USA, INC. | $290.75 | 2020-2022 | |
| Genentech, INC. | $128.10 | 2021-2024 | Xolair |
| Sanofi-Aventis U.S. LLC | $112.34 | 2019-2021 | |
| Blueprint Medicines Corporation | $105.97 | 2023-2025 | Ayvakit |
| Pharming Healthcare, INC. | $97.90 | 2022-2025 | Ruconest |
| Octapharma USA, INC. | $73.29 | 2021-2025 | Panzyga |
| Takeda Pharmaceuticals U.S.A., INC. | $53.84 | 2021-2023 | Cuvitru |
| Boehringer Ingelheim Pharmaceuticals, INC. | $53.62 | 2020-2022 | |
| Lilly USA, LLC | $36.66 | 2023-2025 | Taltz, Ebglyss |
| Grifols USA, LLC | $29.20 | 2022-2024 | Xembify |
| Seqirus USA INC | $26.98 | 2025 | Fluad, Flucelvax |
| Pari Respiratory Equipment, INC. | $26.81 | 2025 | Vortex |
| Leo Pharma INC. | $25.69 | 2022 | |
| Cycle Pharmaceuticals INC | $23.43 | 2025 | Sajazir |
| Abbvie INC. | $19.27 | 2024 | |
| Merck Sharp & Dohme LLC | $18.18 | 2023 | |
| Aytu Biopharma, INC. | $17.90 | 2025 |
6 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Sublett listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.